Literature DB >> 31053774

Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?

Nina D'Abreo1, Sylvia Adams2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31053774     DOI： 10.1038/s41571-019-0216-2

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  17 in total

1.  A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).

Authors:  Sylvia Adams; Megan Othus; Sandip Pravin Patel; Kathy D Miller; Rashmi Chugh; Scott M Schuetze; Mary D Chamberlin; Barbara J Haley; Anna Maria V Storniolo; Mridula P Reddy; Scott A Anderson; Collin T Zimmerman; Anne P O'Dea; Hamid R Mirshahidi; Jordi Rodon Ahnert; Frank J Brescia; Olwen Hahn; Jane M Raymond; David D Biggs; Roisin M Connolly; Elad Sharon; Larissa A Korde; Robert J Gray; Edward Mayerson; Melissa Plets; Charles D Blanke; Young Kwang Chae; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2021-10-29       Impact factor: 13.801

Review 2.  Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives.

Authors:  Huimei Yi; Ying Li; Yuan Tan; Shujun Fu; Faqing Tang; Xiyun Deng
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

3.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.

Authors:  Leisha A Emens; Sylvia Adams; Ashley Cimino-Mathews; Mary L Disis; Margaret E Gatti-Mays; Alice Y Ho; Kevin Kalinsky; Heather L McArthur; Elizabeth A Mittendorf; Rita Nanda; David B Page; Hope S Rugo; Krista M Rubin; Hatem Soliman; Patricia A Spears; Sara M Tolaney; Jennifer K Litton
Journal:  J Immunother Cancer       Date:  2021-08       Impact factor: 13.751

4.  A novel role for an old target: CD45 for breast cancer immunotherapy.

Authors:  Annat Raiter; Oran Zlotnik; Julia Lipovetsky; Shany Mugami; Shira Dar; Ido Lubin; Eran Sharon; Cyrille J Cohen; Rinat Yerushalmi
Journal:  Oncoimmunology       Date:  2021-05-25       Impact factor: 8.110

Review 5.  Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.

Authors:  David B Page; Harry Bear; Sangeetha Prabhakaran; Margaret E Gatti-Mays; Alexandra Thomas; Erin Cobain; Heather McArthur; Justin M Balko; Sofia R Gameiro; Rita Nanda; James L Gulley; Kevin Kalinsky; Julia White; Jennifer Litton; Steven J Chmura; Mei-Yin Polley; Benjamin Vincent; David W Cescon; Mary L Disis; Joseph A Sparano; Elizabeth A Mittendorf; Sylvia Adams
Journal:  NPJ Breast Cancer       Date:  2019-10-08

Review 6.  Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?

Authors:  Claire Deligne; Kim S Midwood
Journal:  Front Oncol       Date:  2021-02-24       Impact factor: 6.244

7.  Xiao-Ai-Ping Injection Enhances Effect of Paclitaxel to Suppress Breast Cancer Proliferation and Metastasis via Activating Transcription Factor 3.

Authors:  Junjun Chen; Xiangqi Zhang; Xiao Xiao; Yawei Ding; Wei Zhang; Meizhi Shi; Jiao Yang; Ying Liu; Yonglong Han
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

8.  Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC.

Authors:  Malvika Sharma; Ravi Chakra Turaga; Yi Yuan; Ganesh Satyanarayana; Falguni Mishra; Zhen Bian; Wei Liu; Li Sun; Jenny Yang; Zhi-Ren Liu
Journal:  J Exp Med       Date:  2021-04-05       Impact factor: 14.307

9.  An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity.

Authors:  Zhuolong Zhou; Kevin Van der Jeught; Yuanzhang Fang; Tao Yu; Yujing Li; Zheng Ao; Sheng Liu; Lu Zhang; Yang Yang; Haniyeh Eyvani; Mary L Cox; Xiyu Wang; Xiaoming He; Guang Ji; Bryan P Schneider; Feng Guo; Jun Wan; Xinna Zhang; Xiongbin Lu
Journal:  Nat Biomed Eng       Date:  2021-11-01       Impact factor: 25.671

10.  Efficacy and safety of Xiaoaiping injection for breast cancer: A protocol for systematic review and meta-analysis.

Authors:  Daorui Hou; Jian Xiong; Yahui Peng; Ya Li; Lu Xiong
Journal:  Medicine (Baltimore)       Date:  2020-08-28       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.